LB-100

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Lixte Biotechnology Holdings, Inc., The Netherlands Cancer Institute, M.D. Anderson Cancer Center

Conditions

Astrocytoma, Grades II, III and IVGiant Cell GlioblastomaGlioblastoma MultiformeGliomaMetastatic Microsatellite-stable Colorectal CancerMyelodysplastic SyndromesOligodendrogliomasOvarian Clear Cell Carcinoma

Phase 1

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

RecruitingNCT03886662

Lixte Biotechnology Holdings, Inc.Myelodysplastic Syndromes

Start: 2019-04-30End: 2021-07-31Target: 47Updated: 2019-04-08

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

RecruitingNCT06012734

The Netherlands Cancer InstituteMetastatic Microsatellite-stable Colorectal Cancer

Start: 2024-06-18End: 2028-07-01Target: 37Updated: 2026-06-29

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

RecruitingNCT06065462

M.D. Anderson Cancer CenterOvarian Clear Cell Carcinoma

Start: 2023-11-10End: 2027-10-01Target: 21Updated: 2026-06-23

Phase 2

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

CompletedNCT03027388

National Cancer Institute (NCI)Astrocytoma, Grades II, III and IV, Giant Cell Glioblastoma, Glioblastoma Multiforme +2

Start: 2019-01-09End: 2022-08-31Updated: 2023-11-22